| 
 | Webcast
ImmunoGen, Inc. at Lazard Capital Markets Healthcare Conference (Replay)
11/18/08 at 1:10 p.m. ET |
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies, and the creation and attachment of potent cell-killing agents. The Company’s TAP technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec and Biotest also are testing T... More >> | | |
 |
Shareholder Inquiries
Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.
| Corporate
Headquarters
ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477
Phone: (781) 895-0600
Email: info@immunogen.com
|
Transfer Agent and Registrar
Mellon Investor Services, LLC
Ridgefield Park, NJ
Phone: (800) 288-9541
www.melloninvestor.com/isd | | Corporate
Counsel
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
Boston, MA | Independent Accountants
Ernst & Young LLP
Boston, MA |
|
Receive E-mail Alerts | | Sign up to receive e-mail alerts whenever ImmunoGen posts new information to the site. Just enter your e-mail address and click Submit. |
|
